NEWS: Neurotrophic factor grant

[Phil Tompkins <philtomp@xxxxxxxxxxx>]

"HOPKINTON, Mass., Oct. 6 /PRNewswire/ -- Creative BioMolecules,
Inc. (Nasdaq: CBMI - news) announced today that it has received a
Phase I Small Business Innovation Research (SBIR) grant from the
National Institutes of Health (NIH) for research into morphogenic
protein-based therapies for the treatment of Parkinson's Disease. The
research is being conducted in collaboration with Paula C. Bickford,
Ph.D., Associate Professor of Pharmacology at the University of
Colorado's School of Medicine.

"Creative BioMolecules has proprietary rights to a family of
neurotrophic proteins with demonstrated activity in multiple animal
models of disease including stroke and initial results in Parkinson's
Disease. This grant will support research to evaluate the potential
of these proteins to restore dopaminergic neurons, the brain cells
damaged in Parkinson's Disease, and promote the reestablishment of
signaling pathways in the central nervous system.

"Dr. Bickford commented, ``Factors that promote the survival or
prevent the progressive deterioration of dopaminergic neurons may
have significant benefit in treating Parkinson's Disease. Early
research indicates that OP-1 may represent the first protein in an
exciting family of neurotrophic factors. ..."

"NOTE: Creative BioMolecules, Inc. makes available its latest news
releases on the Internet at  and
 or by facsimile by calling Fax On Demand at
1-800-758-5804, extension 212213."